Major Infections of Newly Diagnosed Childhood-Onset Systemic Lupus Erythematosus

References

• Wang H, Zhou Y, Yu L, et al. Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study. Lupus Sci Med. 2022;9(1):e000725. doi:10.1136/lupus-2022-000725
   PubMed Web of Science ®Google Scholar
• Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976;60(2):221. doi:10.1016/0002-9343(76)90431-9
   PubMed Web of Science ®Google Scholar
• Ng WL, Chu CM, Wu AK, Cheng VC, Yuen KY. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. Qjm. 2006;99(1):37–47. doi:10.1093/qjmed/hci155
   PubMed Web of Science ®Google Scholar
• Zhao K, Xie H, Li L, Esdaile JM, Aviña-Zubieta JA. Increased risk of severe infections and mortality in patients with newly diagnosed systemic lupus erythematosus: a population-based study. Rheumatology. 2021;60(11):5300–5309. doi:10.1093/rheumatology/keab219
   PubMed Web of Science ®Google Scholar
• Feng PH, Lin SM, Yu CT, et al. Inadequate antimicrobial treatment for nosocomial infection is a mortality risk factor for systemic lupus erythematous patients admitted to intensive care unit. Am J Med Sci. 2010;340(1):64–68. doi:10.1097/MAJ.0b013e3181e0ef9b
   PubMed Web of Science ®Google Scholar
• Lu Z, Li J, Ji J, Gu Z, Da Z. Mortality prediction in systemic lupus erythematosus patients with pulmonary infection. Int J Rheum Dis. 2019;22(6):1077–1083. doi:10.1111/1756-185X.13555
   PubMed Web of Science ®Google Scholar
• Rúa-Figueroa Í, López-Longo J, Galindo-Izquierdo M, et al. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2017;47(1):38–45. doi:10.1016/j.semarthrit.2017.01.010
   PubMed Web of Science ®Google Scholar
• Wu W, Ma J, Zhou Y, et al. Mortality risk prediction in lupus patients complicated with invasive infection in the emergency department: LUPHAS score. Ther Adv Musculoskelet Dis. 2019;11:1759720x19885559. doi:10.1177/1759720X19885559
   PubMed Web of Science ®Google Scholar
• Rianthavorn P, Prurapark P. Infections in hospitalized children with newly diagnosed systemic lupus erythematosus in underresourced areas. Lupus. 2020;29(11):1475–1482. doi:10.1177/0961203320939164
   PubMed Web of Science ®Google Scholar
• He J, Li Z. Dilemma of immunosuppression and infection risk in systemic lupus erythematosus. Rheumatology. 2023;62(Suppl 1):i22–i29. doi:10.1093/rheumatology/keac678
   PubMedGoogle Scholar
• Nunes J, Issa N, Dupuis A, Accoceberry I, Pedeboscq S. Pneumocystis in the era of prophylaxis: do the guidelines have to change? Infection. 2022;50(4):995–1000. doi:10.1007/s15010-022-01790-2
   PubMed Web of Science ®Google Scholar
• Awad M, Sierra CM, Mesghali E, Bahjri K. Twice weekly prophylaxis with trimethoprim/sulfamethoxazole for Pneumocystis jirovecii pneumonia in pediatric oncology patients. J Oncol Pharm Pract. 2021;27(8):1936–1939. doi:10.1177/1078155220979046
   PubMed Web of Science ®Google Scholar
• Hernández-Cruz B, Ponce-de-León-Rosales S, Sifuentes-Osornio J, Ponce-de-León-Garduño A, Díaz-Jouanen E. Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatic diseases. A case-control study. Clin Exp Rheumatol. 1999;17(1):81–87.
   PubMed Web of Science ®Google Scholar
• Hiraki LT, Feldman CH, Marty FM, Winkelmayer WC, Guan H, Costenbader KH. Serious Infection Rates Among Children With Systemic Lupus Erythematosus Enrolled in Medicaid. Arthritis Care Res. 2017;69(11):1620–1626. doi:10.1002/acr.23219
   Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients. Medicine. 2003;82(5):299–308. doi:10.1097/01.md.0000091181.93122.55
   PubMed Web of Science ®Google Scholar
• Herrinton LJ, Liu L, Goldfien R, Michaels MA, Tran TN. Risk of Serious Infection for Patients with Systemic Lupus Erythematosus Starting Glucocorticoids with or without Antimalarials. J Rheumatol. 2016;43(8):1503–1509. doi:10.3899/jrheum.150671
   PubMed Web of Science ®Google Scholar
• Prata AR, Luís M, Assunção H, da Silva JAP, Inês LS. Antimalarial treatment and minimizing prednisolone are associated with lower risk of infection in SLE: a 24-month prospective cohort study. Clin Rheumatol. 2022;41(4):1069–1078. doi:10.1007/s10067-021-05988-x
   PubMed Web of Science ®Google Scholar
• Wu SA, Yeh KW, Lee WI, et al. Impaired phagocytosis and susceptibility to infection in pediatric-onset systemic lupus erythematosus. Lupus. 2013;22(3):279–288. doi:10.1177/0961203312474704
   PubMed Web of Science ®Google Scholar
• Barber MRW, Clarke AE. Systemic lupus erythematosus and risk of infection. Expert Rev Clin Immunol. 2020;16(5):527–538. doi:10.1080/1744666X.2020.1763793
   PubMed Web of Science ®Google Scholar
• Garg S, Unnithan R, Hansen KE, Costedoat-Chalumeau N, Bartels CM. Clinical Significance of Monitoring Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus: a Systematic Review and Meta-Analysis. Arthritis Care Res. 2021;73(5):707–716. doi:10.1002/acr.24155
   Web of Science ®Google Scholar
• Torres-Ruiz J, Mejía-Domínguez NR, Zentella-Dehesa A, et al. The Systemic Lupus Erythematosus Infection Predictive Index (LIPI): a Clinical-Immunological Tool to Predict Infections in Lupus Patients. Front Immunol. 2018;9:3144. doi:10.3389/fimmu.2018.03144
   PubMed Web of Science ®Google Scholar
• Fragoulis GE, Dey M, Zhao S, et al. Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. RMD Open. 2022;8(2):e002726. doi:10.1136/rmdopen-2022-002726
   PubMed Web of Science ®Google Scholar